Hepatitis B virus reactivation in inflammatory bowel diseases.

Immunosuppressive therapy is a standard treatment for inflammatory bowel disease. However, immunosuppressive therapy is associated with severe side effects such as serious infection. In particular, hepatitis B virus (HBV) reactivation is a concern because it often leads to severe or fatal hepatitis. Screening for HBV infection using the the Japan Society of Hepatology guidelines for the management of Hepatitis B Virus infection published by the drafting committee prior to immunosuppressive therapy or chemother- apy is recommended. Observing the guidelines can prevent severe hepatitis.